-

Bristol Myers Squibb Reports Second Quarter Financial Results for 2026

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today reported second quarter 2026 financial results.

Visit the company’s Investor Relations website at http://investor.bms.com to view the detailed second quarter 2026 earnings press release and investor presentation.

The company will host a conference call and live audio webcast for analysts and investors at 8:15 a.m. ET today, July 30, 2026, which is accessible here. Company executives will review financial results with the investment community during the call.

A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes.

About Bristol Myers Squibb: Transforming Patients' Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.

corporatefinancial-news

Contacts

For more information, contact:
Media Relations: media@bms.com
Investor Relations: investor.relations@bms.com

Bristol Myers Squibb

NYSE:BMY

Release Summary
Bristol Myers Squibb Reports Second Quarter Financial Results for 2026
Release Versions
$Cashtags

Contacts

For more information, contact:
Media Relations: media@bms.com
Investor Relations: investor.relations@bms.com

More News From Bristol Myers Squibb

Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA...

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

PRINCETON, N.J.--(BUSINESS WIRE)--U.S. FDA Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma...

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026...
Back to Newsroom